Zkusit zdarma
GH Research PLC

GH Research PLC

GHRS
Cena:
$ 22.12
+0.35 (1.61%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

4:07 20-05-2026

GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression....

These Analysts Revise Their Forecasts On GH Research After Q1 Results

These Analysts Revise Their Forecasts On GH Research After Q1 Results

10:58 15-05-2026

GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday....

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

7:00 14-05-2026

Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses ...

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research Announces Pricing of $117.5 Million Underwritten Offering

8:00 29-04-2026

DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharm...

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

9:00 20-04-2026

DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharm...

Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?

Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?

8:35 20-04-2026

Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump...

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

11:10 25-03-2026

DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharm...

GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3

GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3

17:28 10-03-2026

GH Research PLC remains well-capitalized with $280.7 million in cash, supporting its lead candidate ...

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

7:00 05-03-2026

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP co...

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

9:37 05-01-2026

The U.S. Food and Drug Administration (FDA) on Monday lifted the clinical hold on GH Research Plc's ...

GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision

GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision

8:30 04-01-2026

GH Research is advancing GH001, an inhaled mebufotenin therapy for treatment-resistant depression, w...

GH Research to Announce IND Status for GH001

GH Research to Announce IND Status for GH001

16:01 02-01-2026

DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharma...

Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet

Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet

10:56 10-11-2025

The average of price targets set by Wall Street analysts indicates a potential upside of 130.6% in G...

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

7:00 06-11-2025

Engagement with FDA on GH001 IND complete response ongoing Full dataset from the Phase 2b clinical t...

Depression-Focused GH Research Shares Could See Significant Upside: Analyst

Depression-Focused GH Research Shares Could See Significant Upside: Analyst

14:07 13-10-2025

Needham initiated coverage on Monday for GH Research PLC (NASDAQ:GHRS), citing the company's lead dr...

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

7:00 09-10-2025

DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharma...

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

7:00 07-08-2025

Global pivotal program initiation on track for 2026 Engagement with FDA on GH001 IND complete respon...

atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate

atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate

16:38 23-07-2025

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jeffer...

atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003

atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003

13:08 23-07-2025

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jeffer...

Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade

Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade

10:56 16-07-2025

The average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in G...

close

GH RESEARCH ANNOUNCES FDA LIFTS CLINICAL HOLD ON GH001, CLEARING PATH FOR GLOBAL PHASE 3 INITIATION IN 2026

05-01-2026
GH001 CLEARED BY FDA FOR U.S. CLINICAL INVESTIGATION, ENABLING U.S. SUBJECT ENROLLMENT COMPANY TO SE...
Více zde

GH RESEARCH TO ANNOUNCE IND STATUS FOR GH001

02-01-2026
DUBLIN, JAN. 02, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

06-11-2025
ENGAGEMENT WITH FDA ON GH001 IND COMPLETE RESPONSE ONGOING FULL DATASET FROM THE PHASE 2B CLINICAL T...
Více zde

GH RESEARCH ANNOUNCES NOVEL THERAPIES SYMPOSIUM PRESENTATION AND POSTERS AT THE 2025 ECNP CONGRESS

09-10-2025
DUBLIN, OCT. 09, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

07-08-2025
GLOBAL PIVOTAL PROGRAM INITIATION ON TRACK FOR 2026 ENGAGEMENT WITH FDA ON GH001 IND COMPLETE RESPON...
Více zde

GH RESEARCH ANNOUNCES GLOBAL PIVOTAL PROGRAM PLANS AND FURTHER DEVELOPMENT UPDATES

23-07-2025
DUBLIN, JULY 23, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH SUBMITS COMPLETE IND HOLD RESPONSE TO FDA AHEAD OF SCHEDULE

20-06-2025
DUBLIN, JUNE 20, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH ANNOUNCES ACCEPTANCE OF PHARMACEUTICAL PIPELINE PRESENTATION AND LATE-BREAKING POSTERS AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY 2025 ANNUAL MEETING

15-05-2025
DUBLIN, MAY 15, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMAC...
Více zde

GH RESEARCH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

08-05-2025
DUBLIN, MAY 08, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMAC...
Více zde

GH RESEARCH REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

27-02-2025
PHASE 2B CLINICAL TRIAL OF GH001 IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION ON TRACK FOR COMPLE...
Více zde

GH RESEARCH ANNOUNCES PRICING OF $150 MILLION PUBLIC OFFERING

04-02-2025
DUBLIN, FEB. 05, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH ANNOUNCES PROPOSED PUBLIC OFFERING

03-02-2025
DUBLIN, FEB. 03, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2B TRIAL WITH GH001 IN TRD DEMONSTRATING -15.5 POINT PLACEBO-ADJUSTED MADRS REDUCTION

03-02-2025
DUBLIN, FEB. 03, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH TO PROVIDE UPDATE ON PHASE 2B TRIAL WITH GH001 IN TRD

31-01-2025
DUBLIN, JAN. 31, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH ANNOUNCES PRIMARY ENDPOINT MET IN TWO PHASE 2A POC TRIALS WITH GH001 AND COMPLETION OF ALL FDA REQUESTS TO ADDRESS IND HOLD WITH NO FINDINGS OF RESPIRATORY TOXICITY IN NON-RODENTS

10-01-2025
DUBLIN, JAN. 10, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

14-11-2024
DUBLIN, NOV. 14, 2024 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMA...
Více zde

GH RESEARCH REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

03-09-2024
DUBLIN, SEPT. 03, 2024 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARM...
Více zde

GH RESEARCH ANNOUNCES APPOINTMENT OF DR. VELICHKA “VILLY” VALCHEVA TO CHIEF EXECUTIVE OFFICER

03-09-2024
DUBLIN, IRELAND, SEPT. 03, 2024 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE...
Více zde

GH RESEARCH REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

03-05-2024
DUBLIN, IRELAND, MAY 03, 2024 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE B...
Více zde

GH RESEARCH REPORTS FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

29-02-2024
DUBLIN, IRELAND, FEB. 29, 2024 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE ...
Více zde

GH RESEARCH ANNOUNCES GRANT OF EUROPEAN PATENT COVERING ALL MEBUFOTENIN (5-MEO-DMT) AND MEBUFOTENIN SALT PRODUCTS FOR USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION

18-01-2024
DUBLIN, IRELAND, JAN. 18, 2024 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE ...
Více zde

GH RESEARCH REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

09-11-2023
DUBLIN, IRELAND, NOV. 09, 2023 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE ...
Více zde

GH RESEARCH PROVIDES UPDATES AND GUIDANCE ON ITS CLINICAL DEVELOPMENT PROGRAM FOR GH001 IN TREATMENT-RESISTANT DEPRESSION

29-09-2023
DUBLIN, IRELAND, SEPT. 29, 2023 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE...
Více zde

GH RESEARCH REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

23-08-2023
DUBLIN, IRELAND, AUG. 23, 2023 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE ...
Více zde

GH RESEARCH REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS

11-05-2023
DUBLIN, IRELAND, MAY 11, 2023 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE B...
Více zde

GH RESEARCH REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

02-03-2023
DUBLIN, IRELAND, MARCH 02, 2023 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE...
Více zde

GH RESEARCH PROVIDES BUSINESS UPDATES AND HIGHLIGHTS KEY UPCOMING MILESTONES

09-01-2023
DUBLIN, IRELAND, JAN. 09, 2023 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE ...
Více zde

GH RESEARCH REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

10-11-2022
DUBLIN, IRELAND, NOV. 10, 2022 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE ...
Více zde

GH RESEARCH REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

23-08-2022
DUBLIN, IRELAND, AUG. 23, 2022 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE ...
Více zde

GH RESEARCH REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

18-05-2022
DUBLIN, IRELAND, MAY 18, 2022 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE B...
Více zde

close

Dokumenty nejsou k dispozici

preloader